Old Age and Aerobic Microorganisms of Patients Affected by *Clostridium difficile* Infection are Associated Primarily with the Intestinal Presence of *Clostridium difficile*

Piatti G¹*, Mannini A¹, Schito AM¹, Musso A² and Santori G¹

¹DISC, Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy
²Division of Microbiology, IRCCS San Martino University Hospital - National Institute for Cancer Research, Genoa, Italy

**Abstract**

*Clostridium difficile* infection in human occurs when the organism is present and germinating in the bowel. Old age of patients’ and particular microorganisms in stools are identified as risk factors for the disease onset. We aimed to investigate if risk factors for *C. difficile* infections in a large Italian hospital were connected to *C. difficile* intestinal presence or to germination. Toxin B positivity was linked with age over 65 years (P=0.03), medical hospitalization (P=0.015) and growth of Enterobacteriaceae (P=0.029) and *Enterococcus* (P=0.05) from the same stools. The presence of *tcdB* was even more strictly linked with old age (P=0.005), medicine hospitalization (P=0.012) and growth of Enterobacteriaceae (P=0.003) and *Enterococcus* (P=0.04). Our results indicated that the presence of *C. difficile* in stools, irrespective of being spore or vegetative form, is reliably associated with old age of subjects and fecal presence of viable Enterobacteriaceae and *Enterococcus*.

**Keywords:** *Clostridium difficile* infection; Microbiota; Spore; Enterobacteriaceae; *Enterococcus*

**Introduction**

*Clostridium difficile* (CD) is an anaerobic, spore-forming, Gram-positive bacterium producing cytotoxic toxins, recognized in the 1970 as the cause of antibiotic-associated pseudomembranous colitis [1]. CD infection (CDI) is a major cause of hospital-acquired diarrhea. Despite the great efforts working in the ambit, infections increased in incidence and severity over the past decade and the management became more daunting, causing significant escalation of the related health-care economic burden [2]. The specific antibacterial treatment implies significant and increasing failures, recurring infections and additional modifications of microbial intestinal consortium of treated patients [3]. Prevention of CDI should be essential, but current deficit of knowledge limits the chances to advance in effective preventive measure. These limitations are due to complex CD pathogenicity, mostly concerning the health care CD acquisition and the reasons allowing the shift from bacterial intestinal presence to the infectious disease [2].

It is now ascertained that CDI is most commonly connected to increased age of patients and to changes in normal intestinal biota, the latter most due to antibiotics administration [4,5]. Several variables, individually or together, have been taken into consideration as causes of CDI onset, but little was culled as really clarifying [6,7]. The aim of our study was to analyse clinical data and intestinal presences of cultivable microorganisms to assess if the certain risk factors individually or together, have been taken into consideration as causes of CDI onset. We enrolled, as CD GDH/toxin B negative stools, only samples which GDH and toxin B with a discarding those CD GDH positive and toxin B negative. Data collection and definitions

Diarrhoea was defined as ≥ 3 unformed stools a day during at least two consecutive days. We included in the study stools samples definitely holding CD vegetative forms, i.e., those positive for *tcdB* gene and for both CD glutamate dehydrogenase (GDH) antigen and toxin B product, discarding those CD GDH positive and toxin B negative. We enrolled, as CD GDH/toxin B negative stools, only samples which negativity was confirmed through two different analytic methods. CD spores were assumed as present in samples *tcdB* gene positive and CD GDH/toxin B negative.

**Detection of CD GDH and toxin B in stools**

Diarrhoeic stools were initially analysed for the presence of CD GDH and toxin B with a Rapid Membrane Enzyme Immunoassay, *C. diff* Quik Chek Complete (Techlab Inc.) by 1 hour from arrival to the same regional area. All stools were sent to the Clinical Microbiology Laboratory of San Martino Hospital for detection of CD toxin B. We prospectively collected age, gender, communitarian or nosocomial provenance, and division of hospital admission. A single stool sample from each patient was included. The laboratory performed cultural, genomic, enzyme and automated immunoassay analyses of samples. The Institutional Ethics Committee of San Martino University Hospital approved the study (n. reg. CEA 13/11-Progetto ist Micro 1/2011), by disposing from informed consents.

**Materials and Methods**

**Patients and clinical specimens**

From June 2011 to December 2012, unformed stools were collected from subjects affected by diarrhoea, i.e., 200 inpatients, admitted in San Martino University Hospital of Genoa, Italy, and 18 outpatients from the same regional area. All stools were sent to the Clinical Microbiology Laboratory of San Martino Hospital for detection of CD toxin B. We prospectively collected age, gender, communitarian or nosocomial provenance, and division of hospital admission. A single stool sample from each patient was included. The laboratory performed cultural, genomic, enzyme and automated immunoassay analyses of samples. The Institutional Ethics Committee of San Martino University Hospital approved the study (n. reg. CEA 13/11-Progetto ist Micro 1/2011), by disposing from informed consents.

**Keywords:** *Clostridium difficile* infection; Microbiota; Spore; Enterobacteriaceae; *Enterococcus*

**Introduction**

*Clostridium difficile* (CD) is an anaerobic, spore-forming, Gram-positive bacterium producing cytotoxic toxins, recognized in the 1970 as the cause of antibiotic-associated pseudomembranous colitis [1]. CD infection (CDI) is a major cause of hospital-acquired diarrhea. Despite the great efforts working in the ambit, infections increased in incidence and severity over the past decade and the management became more daunting, causing significant escalation of the related health-care economic burden [2]. The specific antibacterial treatment implies significant and increasing failures, recurring infections and additional modifications of microbial intestinal consortium of treated patients [3]. Prevention of CDI should be essential, but current deficit of knowledge limits the chances to advance in effective preventive measure. These limitations are due to complex CD pathogenicity, mostly concerning the health care CD acquisition and the reasons allowing the shift from bacterial intestinal presence to the infectious disease [2].

It is now ascertained that CDI is most commonly connected to increased age of patients and to changes in normal intestinal biota, the latter most due to antibiotics administration [4,5]. Several variables, individually or together, have been taken into consideration as causes of CDI onset, but little was culled as really clarifying [6,7]. The aim of our study was to analyse clinical data and intestinal presences of cultivable microorganisms to assess if the certain risk factors individually or together, have been taken into consideration as causes of CDI onset. We enrolled, as CD GDH/toxin B negative stools, only samples which GDH and toxin B with a discarding those CD GDH positive and toxin B negative. Data collection and definitions

Diarrhoea was defined as ≥ 3 unformed stools a day during at least two consecutive days. We included in the study stools samples definitely holding CD vegetative forms, i.e., those positive for *tcdB* gene and for both CD glutamate dehydrogenase (GDH) antigen and toxin B product, discarding those CD GDH positive and toxin B negative. We enrolled, as CD GDH/toxin B negative stools, only samples which negativity was confirmed through two different analytic methods. CD spores were assumed as present in samples *tcdB* gene positive and CD GDH/toxin B negative.

**Detection of CD GDH and toxin B in stools**

Diarrhoeic stools were initially analysed for the presence of CD GDH and toxin B with a Rapid Membrane Enzyme Immunoassay, *C. diff* Quik Chek Complete (Techlab Inc.) by 1 hour from arrival to the same regional area. All stools were sent to the Clinical Microbiology Laboratory of San Martino Hospital for detection of CD toxin B. We prospectively collected age, gender, communitarian or nosocomial provenance, and division of hospital admission. A single stool sample from each patient was included. The laboratory performed cultural, genomic, enzyme and automated immunoassay analyses of samples. The Institutional Ethics Committee of San Martino University Hospital approved the study (n. reg. CEA 13/11-Progetto ist Micro 1/2011), by disposing from informed consents.
laboratory. GDH/toxin B negative sample were analysed again with the more sensitive automated immunosassay VIDAS C. difficile GDH and VIDAS C. difficile Tox A/B [8].

Detection of tcdB gene in stools

Bacterial DNA was extracted from stools with the automated device QIAcube (QIAGEN). With DNA template, we performed Real-time polymerase chain reaction (RT-PCR) using RealCycler CDIF (Progenie Molecular), suitable to detect tcdB gene directly from stools, following manufacturer’s instructions. Faecal presence of tcdB indicated presence of toxigenic CD strains, as spores and vegetative forms.

Evaluation of microbial population of stools

Stools specimens were seeded and cultured on agar plates (Columbia, MacConkey, Mannitol Salt Agar, CHROMagar Candida - BBL) in O₂ atmosphere, at 37°C for 24 hours, to value the growth of aerobic and best aerobic bacteria, including Enterobacteriaceae and Pseudomonadaceae families and Enterococcus and Staphylococcus genera, and the growth of yeasts, i.e., Candida genus. Colonies were identified through the growth on selective plates, microbiological tests, such as catalase, oxidase, bile-esculin agar [9] and, when needed, using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).

Thirty stools were also collected in tubes suitable for anaerobic culture (Vacutainer Anaerobic Specimen Collector, BBL), set on blood agar plates (BBL, Bacteroides bile esculin agar) and incubated at 37°C for 48 h in anaerobiosis, to allow Bacteroides fragilis group and Bacteroides fragilis strains, strictly anaerobic bacteria, to grow. We performed PCR analysis on DNA extracted from boiled anaerobic colonies. β-isopropylmalate dehydrogenase gene (iueB) and B. fragilis neuraminidase gene were amplified and revealed on gel electrophoresis for detecting, respectively, the presence of B. fragilis group and B. fragilis, as described elsewhere [10,11].

Statistical analysis

Results were expressed as mean ± standard deviation, the first and third quartile (1Q, 3Q), percentage, and odds ratio (OR) with their 95% confidence intervals (CI). Continuous variables were preliminarily evaluated for normal distribution with the Shapiro-Wilk test, and confidence intervals (CI). Continuous variables were preliminarily evaluated for normal distribution with the Shapiro-Wilk test, and then compared by the non-parametric Wilcoxon-Mann-Whitney test. Categorical variables were compared with the Pearson chi-squared test. The main variables were evaluated by recursive partitioning. Following this approach, a conditional inference tree showing both the cut-points and the P-value of the associated independent test for each node was obtained [12]. Factors associated with presence of CD toxin B or cdtB gene in stools specimens were evaluated by logistic regression. The independent variables that reached statistical significance at univariate analysis were entered into multivariate regression models. Statistical significance was assumed with p-values <0.05 in two-tailed tests. Statistical analysis was performed using the R software/environment (version 3.1.2; R Foundation for Statistical Computing, Vienna, Austria).

Results

Clinical data, detection of CD GDH/toxin B and tcdB, and aerobic faecal microbiota

We enrolled 218 not consecutive patients, whose stools met requirements. Seventy-five subjects were ≤ 65 years and 143 were over. Out of total patients, 178 were lying in internal medicine wards and 22 in different types of division (11 in surgery and 11 in intensive care wards), whereas 18 were outpatients (Table 1). Fourth-two stools were CD GDH/toxin B positive and 176 negative. Most stools carried live aerobic bacteria of the genus Enterococcus (72.5%) and family Enterobacteriaceae (60.5%). Yeasts of the genus Candida and bacteria of the genus Staphylococcus and family Pseudomonaceae grown, respectively, from 42.7%, 32.1% and 7.8 of total stools (Table 2). Amplification for tcdB gene was positive in 72 stools and negative in 146 (Table 3). Among 72 tcdB positive samples, 30 were negative for CD GDH/toxin B.

Clinical data and intestinal microbial growth according to CD GDH/toxin B presence

CD GDH/toxin B positive stools were significantly more frequent than those negative among patients aged over 65 years (P=0.03) and subjects hospitalized in internal medicine wards (P=0.015) (Table 1). Positive stools were more frequent than those negative also among subjects whose stools carried live Enterobacteriaceae and Pseudomonadaceae bacterial families (P=0.029, P=0.007) (Table 2). In specimens showing growth of Enterococcus, an almost significant frequency of CD GDH/toxin B positive specimens occurred (P=0.05), such as a prevalence, not reaching statistical significance, was among specimens showing growth of Candida and Staphylococcus genera. Candida colonies, present in the minor part of total specimens (42.7%), increased until the majority (52.4%) of those positive for CD GDH/
Clinical data and intestinal microbial growth according to CD tcdB presence

By stratifying stool samples for presence and absence of tcdB, a significant difference was observed for both patients age over 65 years and mean age (P=0.005, P=0.043) (Table 3). A frequency significantly higher in patients tcdB positive than in negative was also found for hospitalization in internal medicine wards (P=0.012). Similar difference between tcdB positive and negative stools was observed for faecal presence of Enterobacteriaceae family and Enterococcus genus (P=0.003, P=0.04) (Table 4). The recursive partitioning analysis returned a conditional inference tree where in stool samples tcdB gene node (P=0.019) was associated with presence of Candida and Enterobacteriaceae in 34 patients (Figure 1). Neither specific bacterial species nor the number of species differed after stratifying for presence and absence of tcdB gene (data not shown).

Logistic regression analysis for CD GDH/toxin B presence

In univariate logistic regression analysis performed for presence in stools of CD GDH/toxin B as dependent variable, statistical significance was found for age over 65 years (P=0.023), hospitalization in internal medicine wards (P=0.022), as well as for presence in stools of Enterobacteriaceae (P=0.024) and Pseudomonadaceae families (P=0.005), and Enterococcus (P=0.038). By entering these variables into a multivariate logistic regression model, only age over 65 years resulted no longer significant (Table 5). Although the multivariate model for CD GDH/toxin B presence revealed a high specificity (0.988), the sensitivity was very poor (0.095) (Figure 2A).

Logistic regression analysis for CD tcdB presence

In univariate logistic regression performed for presence in stools of tcdB gene as dependent variable, statistical significance was observed for age over 65 years (P=0.004), hospitalization in internal medicine wards (P=0.01), as well as for presence in stools of Enterobacteriaceae (P=0.002) and Enterococcus (P=0.03). These variables resulted statistically significant when entered into a multivariate logistic regression model (Table 6). The multivariate model for tcdB gene in stools revealed a balanced sensitivity (0.5) and specificity (0.842) (Figure 2B).

Clinical data and microbial growth according to CD GDH/toxin B presence among tcdB positive specimens

We further compared frequency of old age, hospitalization in medical division and growth of best aerobic bacteria among the forty-two patients whose stools were positive for both tcdB gene and
Discussion

The development of CDI in humans depends on two essential events, i.e., the pathogen presence in the gut and its germination, which lead to the production of bacterial toxins [13]. The occurrence of two different basic factors in CDI pathogenesis has made the understanding more difficult than that of most bacterial infections, and complicated over time the diagnosis and the related epidemiology [2,14]. Numerous investigations clearly demonstrated that intestinal biota, now called microbiota, has vital roles in maintaining the physiology of bowel, and that modifications, physiological or therapeutic, are fundamental in CDI onset [15,16]. Advanced age of patients is often characterized by changes of microbiota and is definitely associated with CDI [17]. We focused on a few variables that represent risk factors, to separate and quantify the relative influence they have on CD intestinal presence and on the germination process. We did not consider the exposure to antibiotics, but only some features of bowel biota, because it is ascertained that CDI onset can be independent from drug administration, though to a lesser part. In addition, it is now clear that, when CDI onset depends on antibiotics, the link is represented by modification of intestinal biota and, when not, the microbiota of affected subjects is different from that of healthy people [14].

We assessed demographic and microbiological data according to faecal presence-absence of CD GDH/toxin B and the codifying gene, cdtB. We found a strong connection between CD GDH/toxin B presence and age of patients over 65 years, and between the same toxin positivity and the growth of organisms of family Enterobacteriaceae and genus Enterococcus from the samples. These bacterial groups have emerged as frequently linked to CDI from studies conducted on mice and humans through molecular methods [4,15,16]. We found interesting, although statistically not significant, data on intestinal presence of yeasts of genus Candida, which, identified to a lesser extent among total stools, grew from most part of those positive for CD GDH/toxin B. The intestinal presence of CD toxin B appeared to be connected to a general presence of aerobic microbial families and genera. The lack of species specificity is reflected in previous studies where microbial modifications due to antibiotic therapies, and connected to CDI, though dissimilar among different reports, led to a same change in function [18-20]. These differences allowed the metabolic hypothesis to replace that structural, based on alleged lowering of microbiota in animals and on diminished competition for nutrients and ecological niches [21,22]. Given the different functional and metabolic characteristics of aerobic and anaerobic microorganisms, and a possible different role in CDI onset, we separately examined their growth. We chose culture-based methods to detect live microorganisms and to exclude those stopped in growth by any effective antibiotic therapy.

When we compared the faecal presence of GDH/toxin B with the provenance of samples, we found a strong connection between CDI and staying of patients in medical wards, which contradicts those works where surgery wards or intensive care units stand out among risk factors for the disease [23]. Interestingly, the connection of old age, faecal presence of aerobic microorganisms and medical admission with the mere presence of CD in the stools appeared more significant than the connection with the presence of GDH/toxin B. In particular, age over 65 years emerged as really determinant also in multivariate logistic regression only when we compared for cdtB presence. This aspect suggests that significance of old age in relation to toxin production could be misleading, i.e., due just to the presence of the microorganism in the bowel of patients.

As other authors, we thought that the changes in microbial community and in metabolic environment would allow germination
Organisms grown in stools | Total N. Stools | tcdB Positive Stools | % | tcdB Negative Stools | % | P*  
--- | --- | --- | --- | --- | --- | ---  
Enterobacteriaceae y* | 132 | 60.5 | 54 | 75 | 78 | 53.4
Enterobacteriaceae n** | 86 | 39 | 18 | 25 | 68 | 46.6
Enterococcus y | 158 | 72.5 | 59 | 81.9 | 99 | 67.8
Enterococcus n | 60 | 27.5 | 13 | 18 | 54 | 32.2
Candida y | 93 | 42.7 | 34 | 47.2 | 59 | 40.4
Candida n | 125 | 57.3 | 38 | 52.8 | 87 | 59.6
Staphylococcus y | 70 | 32.1 | 24 | 33.3 | 46 | 31.5
Staphylococcus n | 148 | 67.9 | 48 | 66.7 | 100 | 68.5
Pseudomonadaceae y | 17 | 7.8 | 8 | 11.1 | 9 | 6.2
Pseudomonadaceae n | 201 | 92.2 | 64 | 88.9 | 137 | 93.8

Table 4: Microbial fecal growth according to presence of *Clostridium difficile* tcdB gene in stools; * microbial family or genus grown from stool specimens; ** microbial family or genus not grown from stool specimens; # P value is indicated only when ≤ 0.05.

| Clostridium difficile GDH/toxinB | Univariate | Multivariate |
|---|---|---|
| Gender, male | 1.708 (0.868-3.392) 0.121 | |
| Age | 1.016 (0.997-1.037) 0.097 | |
| Age > 65 years | 2.612 (1.192-6.371) 0.023 | 2.095 (0.903-5.329) 0.098 |
| Provenance, internal medicine | 5.507 (1.588-34.763) 0.022 | 5.572 (1.516-36.475) 0.026 |
| Presence in stools of Enterobacteriaceae | 2.432 (1.160-5.495) 0.024 | 2.724 (1.228-6.528) 0.018 |
| Enterococcus | 2.655 (1.126-7.337) 0.038 | 2.717 (1.079-9.552) 0.046 |
| Candida | 1.626 (0.826-3.129) 0.158 | |
| Staphylococcus | 1.390 (0.679-2.780) 0.356 | |
| Pseudomonadaceae | 4.366 (1.539-12.231) 0.005 | 4.852 (1.571-15.235) 0.005 |

Table 5: Univariate and multivariate analysis of factors associated with presence of *Clostridium difficile* GDH/toxin B in stool specimens.

| Clostridium difficile tcdB gene | Univariate | Multivariate |
|---|---|---|
| Gender, male | 1.025 (0.578-1.808) 0.932 | |
| Age | 1.015 (0.999-1.031) 0.058 | |
| Age > 65 years | 2.651 (1.400-5.254) 0.004 | 2.342 (1.196-4.770) 0.015 |
| Provenance, internal medicine | 3.339 (1.419-9.210) 0.010 | 3.454 (1.423-9.761) 0.010 |
| Presence in stools of Enterobacteriaceae | 2.615 (1.420-4.982) 0.002 | 2.766 (1.453-5.445) 0.002 |
| Enterococcus | 2.154 (1.101-4.451) 0.030 | 2.125 (1.036-4.756) 0.045 |
| Candida | 1.319 (0.746-2.332) 0.339 | |
| Staphylococcus | 1.087 (0.590-1.974) 0.786 | |
| Pseudomonadaceae | 1.902 (0.685-5.201) 0.206 | |

Table 6: Univariate and multivariate analysis of factors associated with presence of *Clostridium difficile* tcdB gene in stool specimens.
Conflict of Interest

The authors declare that there is no conflict of interests.

References

1. Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL (1977) Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 136: 701-715.

2. Bobo LD, Dubberke ER, Kollef M (2011) Clostridium difficile in the ICU: the struggle continues. Chest 140: 1643-1653.

3. Rodrigues R, Barber GE, Ananthakrishnan AN (2016) A comprehensive study of costs associated with recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 7: 1-7.

4. Hopkins MJ, MacFarlane GT (2002) Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 51: 448-454.

5. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wingenaarden E (2011) Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 53: 42-48.

6. Stewart DB, Yacoub E, Zhu J (2012) Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients. J Gastrointest Surg 16: 1566-1572.

7. Nerandzic MM, Pultz MJ, Donskey CJ (2009) Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother 53: 4133-4137.

8. Eastwood K, Elte P, Charlett A, Wilcox M (2009) Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxicogen culture methods. J Clin Microbiol 47: 3211-3217.

9. Garcia LS (2010) Clinical Microbiology procedures handbook. 3th edn. ASM: LSG and Associates, Santa Monica, California, USA.

10. Miki T, Kuwahara T, Nakayama H (2005) Simultaneous detection of Bacteroides fragilis group species by leuB-direct PCR. J Med Invest 52: 101-108.

11. Sharma N, Chaudhry R (2006) Rapid detection of enterotoxigen Bacteroides fragilis in diarrhoeal faecal samples. Indian J Med Res 124: 575-582.

12. Holthorn T, Hornik K, Zeileis A (2006) Unbiased recursive partitioning: A conditional inference framework. J Comput Graph Stat 15: 651-674.

13. Paredes-Sabja D, Shen AJ, Sorg A (2014) Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol 22: 406-416.

14. Marra AR, Edmond MB, Ford BA, Hervaldt LA, Alqiwizani AR, et al. (2016) Failure of risk-adjustment by test method for C. difficile laboratory-identified event reporting. Infect Control Hosp Epidemiol.

15. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, et al. (2011) The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2: 145-158.

16. Culligan EP, Sleator RD (2016) Advances in the microbiome: applications to Clostridium difficile infection. J Clin Med 5: 83.

17. Loo VG, Bourgault AM, Porier L, Lamothe F, Michaud S, et al. (2011) Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365: 1693-1703.

18. Theriot CM, Koenigsknecht MJ, Carlson JR, PE, Hatton GE, Nelson AM, et al. (2014) Antibiotic induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5: 3114.

19. Karlsson S, Burman LG, Akerlund T (2008) Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. Microbiology 154: 3430-3436.

20. Manges AR, Labbe A, Loo VG, Alberton JK, Behr MA, et al. (2010) Comparative metagenomics study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 202: 1877-1884.

21. Wilson KH, Perini F (1988) Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 56: 2610-2614.

22. Vollaiard EJ, Clasener HA (1994) Colonization resistance. Antimicrob Agents Chemother 38: 409-414.

23. Dodek PM, Norena M, Ayas NT, Romney M, Woong H (2013) Length of stay and mortality due to Clostridium difficile infection acquired in the intensive care unit. J Crit Care 28: 335-340.

24. Schubert AM, Rogers MA, Ring C, Mogile J, Petrosino JP, et al. (2011) Microbiome data distinguish patients with Clostridium difficile infection and colonization. J Infect Dis 38: 409-416.

25. Marra AR, Labbe A, Loo VG, Alberton JK, Behr MA, et al. (2010) Comparative metagenomics study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 202: 1877-1884.

26. Antunes LC, Han J, Ferreira RB, Lolic P, Borchers CH, et al. (2011) Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother 55: 3430-3436.

27. Manges AR, Labbe A, Loo VG, Alberton JK, Behr MA, et al. (2010) Comparative metagenomics study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 202: 1877-1884.

28. Wilson KH, Perini F (1988) Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 56: 2610-2614.

29. Vollaiard EJ, Clasener HA (1994) Colonization resistance. Antimicrob Agents Chemother 38: 409-414.

30. Dodek PM, Norena M, Ayas NT, Romney M, Woong H (2013) Length of stay and mortality due to Clostridium difficile infection acquired in the intensive care unit. J Crit Care 28: 335-340.

31. Schubert AM, Rogers MA, Ring C, Mogile J, Petrosino JP, et al. (2011) Microbiome data distinguish patients with Clostridium difficile infection and colonization. J Infect Dis 38: 409-416.

32. Marra AR, Labbe A, Loo VG, Alberton JK, Behr MA, et al. (2010) Comparative metagenomics study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 202: 1877-1884.

33. Antunes LC, Han J, Ferreira RB, Lolic P, Borchers CH, et al. (2011) Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother 55: 1494-1503.

34. Giel JL, Sorg JA, Sonenshein AL, Zhu J (2010) Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One 5: e8740.

35. Young VB (2016) Therapeutic manipulation of the microbiota: past, present, and considerations for the future. Clin Microbiol Infect.

36. Khoruts A, Dicksee J, Janssen JK, Sadowsky MJ (2010) Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44: 354-360.
29. Theriot CM, Young VB (2014) Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection. Gut Microbes 5: 86-95.

30. Seekatz AM, Theriot CM, Molloy CT, Wozniak KL, Bergin IL, et al. (2015) Fecal microbiota transplantation eliminates Clostridium difficile in a murine model of relapsing disease. Infect Immun 83: 3838-3846.